Science News
from research organizations

Combination therapy incorporating three new agents shows promise as treatment for aggressive lymphoma

Date:
April 20, 2016
Source:
Roswell Park Cancer Institute
Summary:
New research shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies.
Share:
FULL STORY

New research from Roswell Park Cancer Institute (RPCI) shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans.

Priyank Patel, MD, a fellow in the Department of Medicine at Roswell Park, is the first author and Francisco Hernandez-Ilizaliturri, MD, Clinical Chief of the Institute's Lymphoma/Myeloma Service, is the senior author of "Investigating novel targeted therapies for double hit diffuse large B-cell lymphoma (DH-DLBCL)" (abstract 3038), which will be presented on Tuesday, April 19, at 8 a.m. CDT.

Diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, is an aggressive form of lymphoma. This research team reviewed a database of 650 patients with diffuse large B-cell lymphoma, identifying 36 patients whose tumors had two or more aberrant genes. Patients with mutations of the c-MYC, BCL2 and/or BCL6 genes -- a subtype known as "double-hit lymphoma" -- have especially have poor outcomes when treated with standard chemotherapy. The scientists evaluated the effectiveness of three novel anticancer drug candidates that targeted those proteins. In preclinical studies, the therapeutic agents ABT-199, JQ-1 and carfilzomib induced cell death in a dose- and time-dependent manner. Significant synergistic activity was observed when researchers combined ABT199 with carfilzomib and, to a lesser extent, with JQ1 in cancer cell lines.

"Increasing knowledge of genetics and molecular pathways has helped us identify a subgroup of patients who harbor aggressive aberrant gene mutations. Understanding the mechanisms of action and clarifying how these potential therapies work to inhibit cancer cell growth may result in improved outcomes for patients diagnosed with this aggressive type of lymphoma," says Dr. Hernandez-Ilizaliturri.

"As we continue to gain more insight into the finer aspects of cancer biology by understanding the molecular pathways through which the cancer cells grow, we can identify strategies to effectively exploit the growth mechanism of these tumors and hopefully translate that knowledge into improved cure rates for our patients," adds Dr. Patel.

The research was funded, in part, by a generous donation from Carl and Noreen Spezio.


Story Source:

Materials provided by Roswell Park Cancer Institute. Note: Content may be edited for style and length.


Cite This Page:

Roswell Park Cancer Institute. "Combination therapy incorporating three new agents shows promise as treatment for aggressive lymphoma." ScienceDaily. ScienceDaily, 20 April 2016. <www.sciencedaily.com/releases/2016/04/160420090410.htm>.
Roswell Park Cancer Institute. (2016, April 20). Combination therapy incorporating three new agents shows promise as treatment for aggressive lymphoma. ScienceDaily. Retrieved May 24, 2017 from www.sciencedaily.com/releases/2016/04/160420090410.htm
Roswell Park Cancer Institute. "Combination therapy incorporating three new agents shows promise as treatment for aggressive lymphoma." ScienceDaily. www.sciencedaily.com/releases/2016/04/160420090410.htm (accessed May 24, 2017).

RELATED STORIES